Magnesium: Emerging Potentials in Anesthesia Practice

Bansal, Teena

doi:10.4172/2155-6148.1000547

Cited by 8 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 21.6% difference in the MS dose administered in the groups did not result signi cant difference in the resulting magnesium blood concentrations. These concentrations were always within the safe values for patients in the study 31 .…”

Section: Discussionsupporting

confidence: 54%

Strategy to calculate magnesium sulfate dose in obese patients: A randomized blind trial

Filho

Klinsky

Vieira

2021

Preprint

View full text Add to dashboard Cite

BACKGROUNDMagnesium sulfate has analgesic properties in the postoperative period. Among obese patients, there is a gap in the knowledge of its pharmacology related to the use of real, ideal, or corrected ideal body weight in calculating its dose. This trial compared postoperative analgesia using actual and corrected ideal body weight.METHODSSeventy-five obese patients scheduled to undergo laparoscopic cholecystectomy under general anesthesia were randomly assigned to three groups. Patients in the control group received no magnesium sulfate; patients in the other two groups received magnesium sulfate 40 mg·kg− 1 of actual body weight or corrected ideal body weight. A ten nonobese patients group helped us as a model of the expected blood magnesium concentration after magnesium sulfate administration in general population.RESULTSPatients from the groups receiving magnesium sulfate showed significant reduction in morphine consumption (p ≤ 0.001) and pain scores (p = 0.006) in the postoperative period compared to the control group. There was no significant difference in the consumption of morphine (p = 0.323) or pain scores (p = 0.082) between these groups. There was no difference in the total duration of neuromuscular block induced by cisatracurium among the three groups (p = 0.181) or in the blood magnesium concentrations throughout the study.CONCLUSIONSMagnesium sulfate decreased postoperative pain and morphine consumption without affecting cisatracurium recovery time in obese patients undergoing laparoscopic cholecystectomy. Analgesic profile was similar in groups receiving magnesium sulfate calculated through real or corrected ideal body weight.TRIAL REGISTRATIONclinicaltrials.gov NCT04003688. (Date of registration: June 24, 2019)

show abstract

Section: Discussionsupporting

confidence: 54%

Strategy to calculate magnesium sulfate dose in obese patients: A randomized blind trial

Filho

Klinsky

Vieira

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Tese concentrations were similar to the blood magnesium concentrations in the NOG (10 patients). Tese concentrations were always within the safe values for study patients [25], as reported by Taheri et al [10]. Although they did not analyze the analgesic properties, Brookfeld et al [26] found that obese pregnant women needed a longer time to reach a therapeutic concentration of magnesium in the blood for seizure prophylaxis in preeclampsia, which was higher than the average concentration in the present trial and may be higher than the level needed to achieve postsurgical analgesia, which was higher than the average concentration in the present trial.…”

Section: Discussionmentioning

confidence: 82%

Strategy for Calculating Magnesium Sulfate Dose in Obese Patients: A Randomized Blinded Trial

Filho

Klinsky

Gonzalez

et al. 2022

Anesthesiology Research and Practice

View full text Add to dashboard Cite

Background. Magnesium sulfate has analgesic properties during the postoperative period. However, there is a knowledge gap in pharmacology related to the use of the real, ideal, or corrected ideal body weight to calculate its dose in obese patients. This trial compared postoperative analgesia using actual and corrected ideal body weight. Methods. Seventy-five obese patients scheduled to undergo laparoscopic gastroplasty or cholecystectomy under general anesthesia were randomly assigned to three groups. The patients in the control group did not receive magnesium sulfate; the other two groups received magnesium sulfate at 40 mg·kg−1 of actual body weight or corrected ideal body weight. Results. In patients with body mass index >30 mg·kg−2 (mean body mass index ranging from 32.964 kg·m−2 to 33.985 kg·m−2, according to the groups) scheduled for video laparoscopic cholecystectomy, there were no differences in the blood magnesium concentrations in the groups receiving magnesium sulfate throughout the study, regardless of whether the strategy to calculate its dose was based on total or corrected ideal body weight. Patients in the groups receiving magnesium sulfate showed a significant reduction in morphine consumption ( p ≤ 0.001 ) and pain scores ( p = 0.006 ) in the postoperative period compared to those in the control group. There were no significant differences in morphine consumption ( p = 0.323 ) or pain scores ( p = 0.082 ) between the two groups receiving magnesium sulfate. There were no differences in the total duration of neuromuscular block induced by cisatracurium among the three groups ( p = 0.181 ). Conclusions. Magnesium sulfate decreased postoperative pain and morphine consumption without affecting the recovery time of cisatracurium in obese patients undergoing laparoscopic cholecystectomy. Strategies to calculate the dose based on the actual or corrected ideal body weight had similar outcomes related to analgesia and the resulting blood magnesium concentration. However, as the sample in this trial presented body mass indices ranging from 30.11 kg·m−2 to 47.11 kg/m−2, further studies are needed to confirm these findings in more obese patients, easily found in centers specialized.

show abstract

“…Segundo Coderre (1993) o magnésio bloqueia as correntes induzidas por NMDA de maneira dependente de voltagem, bloqueando os efeitos do canal receptor. Bansal (2015) ressaltou que a faixa normal de magnésio no plasma é 1,4-2,2 meq/l. A hipomagnesimia pode ocorrer com frequência após cirurgias como cirurgia abdominal, ortopédica e cardíaca, bem como após pequenas cirurgias.…”

Section: Discussionunclassified

Uso Do Sulfato De Magnésio Para O Tratamento Da Dor Crônica Oncológica

Longoni¹,

Sturion²

2019

Rev. Uningá

View full text Add to dashboard Cite

O uso do sulfato de magnésio como fármaco adjuvante em anestesia, tem aumentado recentemente. Tem como intuito poupar a utilização de opióides e bloqueadores musculares durante as cirurgias. Publicações científicas têm mostrado resultados satisfatórios na utilização do sulfato de magnésio. Seu papel é importante na analgesia multimodal para o tratamento da dor aguda e no alívio da dor pós-operatória, diminuindo a necessidade do uso de medicações analgésicas nesta etapa, mostrando ser uma boa alternativa para o controle e manejo da dor. Devido ao alto índice de dor e ao demasiado consumo de opióides pelos pacientes oncológicos, a dificuldade do controle da dor nestes pacientes tem se mostrado de difícil manejo, uma vez que muitos destes se tornam tolerantes e resistentes aos medicamentos. Por meio deste artigo, busca-se mostrar a utilidade do sulfato de magnésio e as vantagens que o uso desta medicação pode proporcionar a estes pacientes.

show abstract

Magnesium: Emerging Potentials in Anesthesia Practice

Cited by 8 publications

References 51 publications

Strategy to calculate magnesium sulfate dose in obese patients: A randomized blind trial

Strategy to calculate magnesium sulfate dose in obese patients: A randomized blind trial

Strategy for Calculating Magnesium Sulfate Dose in Obese Patients: A Randomized Blinded Trial

Uso Do Sulfato De Magnésio Para O Tratamento Da Dor Crônica Oncológica

Contact Info

Product

Resources

About